Recent developments include leadership changes, quarterly financial results showing fluctuating losses, product launches, certifications, government contracts, and updates on indemnification and leadership arrangements.

• Astrotech updated indemnification and leadership arrangements in February 2026 [N1].
• The company reported a decrease in Q2 losses as of February 2026 [N2].
• Full year losses increased as reported in September 2025 [N3].
• Jennifer Cañas was appointed Chief Financial Officer in May 2025 [N4].
• Q3 Fiscal Year 2025 financial results and product development milestones were reported in May 2025 [N5].
• Astrotech launched an enhanced TRACER 1000 Narcotics Trace Detector in March 2025 [N6].
• The company launched EN-SCAN, Inc. for environmental testing solutions in February 2025 [N7].
• Q2 Fiscal Year 2025 financial results and developments were reported in February 2025 [N8].

Astrotech's proprietary AMS Technology platform addresses significant limitations of existing detection technologies by offering higher accuracy, lower false alarm rates, and expanded detection capabilities. The TRACER 1000™ ETD's certifications and approvals from European and U.S. authorities enable access to large security markets including airports, cargo, and border security. The launch of the TRACER 1000 Narcotic Trace Detector targets the growing synthetic drug crisis, potentially expanding market opportunities. AgLAB's mass spectrometry solutions for hemp and cannabis processing address a rapidly evolving and expanding industry with potential for improved product quality and operational efficiencies. Government contracts and GSA schedule listings facilitate sales to federal agencies. The company's strong liquidity ratios as of March 31, 2026, provide a buffer for ongoing operations and development.

Astrotech has incurred significant losses since inception and continues to report net losses, resulting in an accumulated deficit of approximately $262 million as of March 31, 2026. The company requires additional capital to fund operations and product development, with no assurance that financing will be available on acceptable terms. Failure to raise capital could force scaling back or discontinuation of product development, asset disposals, or even bankruptcy. The company's common stock faces risks related to maintaining Nasdaq listing requirements, including a proposed rule that could accelerate delisting if market value falls below $5 million. Delisting could materially reduce liquidity, market price, and access to capital. Competition from established technologies and regulatory hurdles in certification processes pose ongoing challenges. Market fragmentation and regulatory uncertainties in target industries such as hemp and cannabis may impact growth prospects.

Astrotech's moat is based on its proprietary AMS Technology platform, which offers advantages over traditional mass spectrometry and ion mobility spectrometry devices, including smaller size, lower cost, ease of use, and higher accuracy with fewer false alarms. The company holds 16 patents and extensive trade secrets protecting its technology. Its TRACER 1000™ explosives trace detector is the first mass spectrometry-based ETD certified by the European Civil Aviation Conference and approved by the U.S. TSA for air cargo, providing a competitive edge in security markets. The technology's ability to expand its threat detection library without degrading performance differentiates it from IMS-based competitors. Additionally, Astrotech's strategy of commercializing through specialized subsidiaries allows focused market penetration in security, agriculture, and environmental testing sectors. However, the company faces competition from established technologies and must continue innovation and certification to maintain its position.

• Capital and Liquidity Risk: The company has incurred significant losses and an accumulated deficit, requiring additional capital to fund operations and product development. There is no assurance that financing will be available on acceptable terms or at all, which could materially impact the company's ability to continue operations.
• Nasdaq Listing Risk: Astrotech's common stock is listed on the Nasdaq Capital Market and must meet continued listing requirements. Proposed Nasdaq rules could lead to accelerated delisting if market value falls below $5 million, which would reduce liquidity, market price, and access to capital.
• Product Development and Certification Risk: The company depends on successful development, testing, and certification of its products such as the TRACER 1000 ETD and NTD. Delays or failures in certification processes could limit market acceptance and sales.
• Market and Competitive Risk: Astrotech operates in competitive markets with established technologies. The company must continue to innovate and differentiate its products to maintain and grow market share. Market fragmentation and regulatory changes in industries like hemp and cannabis add uncertainty.

• Astrotech Corporation (Nasdaq: ASTC) is a Delaware corporation organized in 1984.
• The company develops and commercializes mass spectrometry and gas chromatography analytical devices for real-time chemical detection in high-volume environments such as airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers, and industrial locations.
• Astrotech's proprietary technology includes the Astrotech Mass Spectrometer Technology (AMS Technology) and ATi Gas Chromatography Column (GC) platforms, designed to simplify user interface, automate calibration, ruggedize components for field use, and enable multiple sample intake configurations.
• The AMS Technology platform is commercialized through wholly owned subsidiaries, including Astrotech Technologies, Inc. (ATI), 1st Detect Corporation, and AgLAB Inc.
• ATI owns and licenses the AMS Technology, which is designed to be smaller, less expensive, and easier to use than traditional mass spectrometers, operating under ultra-high vacuum to reduce false alarms.
• 1st Detect Corporation develops security and detection applications, including the TRACER 1000™, the first mass spectrometry-based explosives trace detector (ETD) certified by the European Civil Aviation Conference (ECAC) and approved by the U.S. Transportation Security Administration (TSA) for air cargo.
• The TRACER 1000 ETD is deployed in approximately 37 locations across 16 countries in the U.S., Europe, and Asia as of March 31, 2026.
• The TRACER 1000 has an extensive and expandable threat detection library, which contrasts with ion mobility spectrometry (IMS)-based ETDs that have limited libraries and higher false positive rates.
• The company is conducting TSA Stage II testing and developmental test and evaluation for checkpoint certification of the TRACER 1000.
• 1st Detect also launched the TRACER 1000 Narcotic Trace Detector (NTD) to detect synthetic opiates and novel psychoactive substances, addressing the global drug crisis.
• The TRACER 1000 ETD and NTD are listed on the U.S. General Services Administration (GSA) IT Schedule 70, enabling sales to the U.S. federal government.
• In January 2025, 1st Detect was awarded a Department of Homeland Security (DHS) contract to develop next-generation explosives trace detection technology.
• AgLAB Inc. licenses AMS Technology for agricultural applications, focusing on hemp and cannabis markets with the AgLAB 1000™ series mass spectrometers.
• AgLAB's products aim to optimize yields in hemp and cannabis oil distillation, using the Maximum Value Process (MVP) for real-time analysis to improve product quality and quantity.
• AgLAB has entered into a master lease agreement with SC Laboratories to jointly market the AgLAB 1000-D2™ mass spectrometer and MVP testing method.
• Financial snapshot as of March 31, 2026: cash and equivalents of $2.679 million, current assets of $11.329 million, current liabilities of $1.835 million, current ratio of 6.17, and cash ratio of 3.4.
• The company reported a net loss of $3.768 million for the quarter ended March 31, 2026, and an accumulated deficit of approximately $262 million as of that date.
• Basic earnings per share were -$2.25 for the quarter ended March 31, 2026.
• The company has incurred significant losses since inception and anticipates continued losses, requiring additional capital to fund operations and product development.
• Astrotech's common stock is listed on the Nasdaq Capital Market and faces risks related to maintaining listing requirements, including a proposed Nasdaq rule requiring a minimum market value of $5 million in listed securities.
• Failure to maintain Nasdaq listing could materially reduce liquidity, market price, and ability to raise capital, and could lead to delisting proceedings.
• Recent leadership changes include the appointment of Jennifer Cañas as Chief Financial Officer in May 2025.
• The company has launched new products and subsidiaries, including the enhanced TRACER 1000 NTD and EN-SCAN, Inc. for environmental testing solutions.
• The TRACER 1000 system achieved ECAC/EU G1 approval in May 2026, meeting high European aviation security standards.
• The company has received purchase orders and sales for TRACER 1000 ETD and NTD products, including a $429,000 order from Intuitive Research and Technology Corporation in early 2025.
• Recent news includes updates on indemnification and leadership arrangements, quarterly financial results showing fluctuating losses, and product development milestones.